What is the antibody-drug conjugates market growth?

Antibody Drug Conjugate Market Analysis

The global antibody drug conjugate market is projected to witness a stupendous growth at a notable 16.70% CAGR over the predicted years. ADCs are made of three parts- first a specific antibody for binding, an antigen that has limited expression on the normal cells, second a cytotoxic agent to kill target cancer cells and third a chemical linker to attach the cytotoxic agent to the antibody. This is how antibody drug conjugates work. They are the new age of therapeutic agents. One of the key advantages of antibody drug conjugates is that this will help in bringing together the finest characteristics of both antibodies as well as the chemotherapy’s cytotoxic potential.

There are many factors that is fuelling the growth of the antibody drug conjugate market. The different antibody drug conjugate market trends and factors in this market according to an analysis performed by Market Research Future (MRFR) include increasing prevalence of cancer, advancement in medical technology, increased investment in R & D, efficacy of ADC in treating diseases, rising collaboration amid biotechnology and biopharmaceuticals and research institutes, preclinical research, growing geriatric population and rise in obese population. On the contrary, the soaring cost related to the procedure may hamper the growth of the antibody drug conjugate market.

Regional Analysis

Based on region, the antibody drug conjugate market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America is expected to accrue maximum share in the market due to advancement in manufacturing techniques, technological innovation and contribution of nanotechnology to create ADC. The U.S. FDA has given approval to only three ADC. The antibody drug conjugate market in Europe will have the second largest share followed by the APAC region. APAC is an emerging market and the factors that are driving the growth of the market include increasing government initiatives. A good number of products are under the pipeline and such developments are performed under license agreements.

Market Segmentation

As per MRFR report, the global antibody drug conjugate market is segmented on the basis of type, product, technology, application and end-user.

Based on type, it is segmented into drug/toxin, linker, monoclonal antibodies and others. Of these, the antibody drug conjugate linker is expected to have the maximum antibody drug conjugate market share.

Based on application, the antibody drug conjugate market is segmented into lymphoma, multiple myeloma, solid tumors, skin cancer, breast cancer, colon cancer, lung cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate cancer and leukemia. Leukemia is further segmented into Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Acute Myeloid Leukemia (AML). Of these, breast cancer had the maximum share owing to its increasing prevalence.

Based on product, it is segmented into Kadcyla, Adcertis and others.

Based on technology, the antibody drug conjugate market is segmented into Immunomedics technology, Seattle Genetics technology, ImmunoGen technology and others.

Based on end-user, it is segmented into biopharmaceutical companies, biotechnology companies, academic research institutes, specialized cancer and others.

Key Players

Leading players profiled in the antibody drug conjugate market include Synthon (U.S.), Mersana Therapeutics (U.S.), Oxford BioTherapeutics (U.S.), Heidelberg Pharma (Germany), Progenics Pharmaceuticals (U.S.), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Agensys, Inc. (U.S.), Concortis Biotherapeutics (U.S.), Genentech (U.S.), AbbVie Inc. (U.S.), Millennium Pharmaceuticals (U.S.), Celldex Therapeutics (U.S.), Pfizer Inc. (U.S.), Immunomedics (U.S.), Antikor (U.K.), Roche Holding AG (Switzerland), ImmunoGen, Inc. (U.S.), and Seattle Genetics (U.S.).

Feb 2019- The Food and Drug Administration (FDA) has granted priority review to ADC (antibody drug conjugate) for diffusing large B-Cell Lymphoma. The chief medical officer of global product development is working with the Food and Drug Administration for bringing this vital novel option to patients having this aggressive ailment as fast as possible. The FDA is most likely to come up with the decision by August 19, 2019.

Jan 2019- Daiichi Sankyo has come up with a late-stage study of ADC to treat patients having low expressing HER2 metastatic/unresectable breast cancer.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Respiratory Care Devices Market Manufacturer Landscape, Revenue, Volume Analysis and Segment Information up to 2030

  Respiratory Care Devices Market Highlights Respiratory care devices are used for treating, controlling, evaluating, managing, and diagnosing patients with an anomaly in the cardiopulmonary system. The respiratory disease is any of the diseases and disorders of the airways and the lungs that affect human breathing. Diseases of the respiratory system may disturb any of the structures and organs that have to do with breathing, which includes nasal cavities, the throat, the larynx, the trachea, the tissues of the lungs, and the respiratory muscles of the chest cage. The growing respiratory diseases are largely due to increasing patient population suffering from chronic diseases, which include chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, and asthma. The initial detection of these diseases aids in providing better treatments. Thus, the demand for respiratory care devices market is increasing greatly in the global market. Additionally, the growing elder...
Read more

Medical Imaging Workstations Market Tendencies, Revenue Forecast and Interesting Opportunities from 2022 to 2030

  Medical Imaging Workstations Market Highlights The global medical imaging workstations market is projected to reach USD 6.22 Billion by 2030 at 6.9% CAGR during the forecast period 2022-2030. The medical imaging workstations has become a base technology of modern medical diagnostics for the treatment of variety of acute and chronic diseases including cardiovascular diseases and cancer. The usage of medical imaging workstations market has reduced manual workflow and increased the accuracy and precision of diagnosis tremendously in recent years. The factors influencing the growth of the market including growing government investment and funding’s for research in modernization of imaging services, favourable reimbursement policies and the on-going technological advancements in imaging systems to improve healthcare infrastructure is anticipated to boost the growth of the market over the forecast period. Additionally, increasing demand for diagnostic imaging devices and develo...
Read more

Population Health Management Market | Industry Analysis, Size, Growth, Key Players, Segmentation And Forecast By 2030

  Global Population Health Management Market - Overview The global  population health management market  is growing with the rapid pace; mainly due to the technological innovation. According to a recent study report published by the Market Research Future, the global population health management is booming and expected to gain prominence over the forecast period growing rapidly. The market is forecasted to demonstrate a spectacular growth by 2030, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2022 – 2030). Notably, extreme need to fill in the gap between expenditure and outcomes is the key factor driving the  eclinicalworks population health  management market. It is observed that in the year 2012 digital healthcare data was estimated to be around 500 petabytes and is expected to reach 25,000 petabytes by 2020. On the other hand there has been deterioration in clinical outcomes in spite of huge expen...
Read more